FibroGen (NASDAQ:FGEN). (NASDAQ: FGEN) is a biopharmaceutical company focused on the discovery, development and commercialization of therapies that address severe unmet medical needs in the areas of fibrosis and anemia. Since its founding in 1993 and establishment in San Francisco, FibroGen has pursued a research‐driven approach to translate insights from hypoxia biology and fibrotic pathways into novel medicines. The company’s work centers on small molecules and biologics designed to modulate key molecular targets implicated in chronic kidney disease, idiopathic pulmonary fibrosis, muscular dystrophies and oncology.
The company’s lead product is roxadustat, an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHI) for the treatment of anemia in chronic kidney disease. Roxadustat has received approvals in China, Japan and the European Union and is marketed in partnership with Astellas and AstraZeneca outside of China. In addition to roxadustat, FibroGen is developing pamrevlumab, a fully human monoclonal antibody targeting connective tissue growth factor (CTGF), in indications such as idiopathic pulmonary fibrosis, pancreatic cancer and Duchenne muscular dystrophy. FibroGen’s pipeline also includes preclinical programs in other fibrotic and inflammatory diseases.
FibroGen maintains research and development facilities in North America, Asia and Europe, supporting a global network of clinical trials and regulatory activities. The company collaborates with strategic partners to accelerate late‐stage development and commercialization, while internal teams drive early research and translational science. With a presence in key markets around the world, FibroGen aims to bring innovative therapies to patients suffering from debilitating, progressive conditions.
Led by a seasoned executive team with backgrounds in biopharmaceutical R&D, clinical development and global commercialization, FibroGen combines scientific rigor with practical expertise. The company’s leadership has overseen the transition from discovery through approval and launch of its first marketed product, positioning FibroGen as a specialized biopharma player dedicated to improving patient outcomes in chronic and life-threatening diseases.
